NEW YORK (Reuters Health) – Among patients with type 2 diabetes, those taking a once-daily extended-release formulation of glipizide are more compliant with treatment than those taking a twice-daily immediate-release formulation.
In a retrospective study based on data from a pharmacy benefit management database, Christopher M. Dezii and colleagues, from Bristol-Myers Squibb Co., Princeton, New Jersey, examined differences in adherence and persistence with prescribed therapy in patients new to once-daily glipizide gastrointestinal therapeutic system (GITS) or to twice -daily (BID) glipizide..
Patients in the GITS group had an adherence rate of 60.5% while their mean pill-count per day was 2.25, compared with 52.0% adherence in the BID group with a daily pill-count of 2, according to the report in the January issue of the Southern Medical Journal. At 12 month, persistence rates were 44.4% and 35.8% in the GITS and BID groups, respectively.
"These data suggest that dosing frequency exerts a greater impact on patient adherence and persistence than number of tablets per dose," the investigators conclude.
South Med J 2002;95:68-71.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!